Purvalanol A, Olomoucine II and Roscovitine Inhibit ABCB1 Transporter and Synergistically Potentiate Cytotoxic Effects of Daunorubicin In Vitro

被引:25
作者
Cihalova, Daniela [1 ]
Hofman, Jakub [1 ]
Ceckova, Martina [1 ]
Staud, Frantisek [1 ]
机构
[1] Charles Univ Prague, Fac Pharm Hradec Kralove, Dept Pharmacol & Toxicol, Hradec Kralove, Czech Republic
关键词
CANCER RESISTANCE PROTEIN; DEPENDENT KINASE INHIBITOR; SELICICLIB R-ROSCOVITINE; P-GLYCOPROTEIN; MULTIDRUG-RESISTANCE; ABCG2; TRANSPORTER; PHASE-I; FLAVOPIRIDOL; CHEMOTHERAPY; PENETRATION;
D O I
10.1371/journal.pone.0083467
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Cyclin-dependent kinase inhibitors (CDKi) have high potential applicability in anticancer therapy, but various aspects of their pharmacokinetics, especially their interactions with drug efflux transporters, have not yet been evaluated in detail. Thus, we investigated interactions of five CDKi (purvalanol A, olomoucine II, roscovitine, flavopiridol and SNS-032) with the ABCB1 transporter. Four of the compounds inhibited efflux of two ABCB1 substrates, Hoechst 33342 and daunorubicin, in MDCKII-ABCB1 cells: Olomoucine II most strongly, followed by roscovitine, purvalanol A, and flavopiridol. SNS-032 inhibited ABCB1-mediated efflux of Hoechst 33342 but not daunorubicin. In addition, purvalanol A, SNS-032 and flavopiridol lowered the stimulated ATPase activity in ABCB1 membrane preparations, while olomoucine II and roscovitine not only inhibited the stimulated ATPase but also significantly activated the basal ABCB1 ATPase, suggesting that these two CDKi are ABCB1 substrates. We further revealed that the strongest ABCB1 inhibitors (purvalanol A, olomoucine II and roscovitine) synergistically potentiate the antiproliferative effect of daunorubicin, a commonly used anticancer drug and ABCB1 substrate, in MDCKII-ABCB1 cells as well as in human carcinoma HCT-8 and HepG2 cells. We suggest that this pronounced synergism is at least partly caused by (i) CDKi-mediated inhibition of ABCB1 transporter leading to increased intracellular retention of daunorubicin and (ii) native cytotoxic activity of the CDKi. Our results indicate that co-administration of the tested CDKi with anticancer drugs that are ABCB1 substrates may allow significant dose reduction in the treatment of ABCB1-expressing tumors.
引用
收藏
页数:11
相关论文
共 46 条
[1]   Roscovitine synergizes with conventional chemo-therapeutic drugs to induce efficient apoptosis of human colorectal cancer cells [J].
Abaza, Mohamed Salah I. ;
Bahman, Abdul-Majeed A. ;
Al-Attiyah, Rajaa J. .
WORLD JOURNAL OF GASTROENTEROLOGY, 2008, 14 (33) :5162-5175
[2]   Biochemical, cellular, and pharmacological aspects of the multidrug transporter [J].
Ambudkar, SV ;
Dey, S ;
Hrycyna, CA ;
Ramachandra, M ;
Pastan, I ;
Gottesman, MM .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1999, 39 :361-398
[3]   Seliciclib (CYC202, R-roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft model [J].
Appleyard, Maria Virginia C. L. ;
O'Neill, Mary A. ;
Murray, Karen E. ;
Paulin, Fiona E. M. ;
Bray, Susan E. ;
Kernohan, Neil M. ;
Levison, David A. ;
Lane, David P. ;
Thompson, Alastair M. .
INTERNATIONAL JOURNAL OF CANCER, 2009, 124 (02) :465-472
[4]   The role of multidrug, transporters in drug availability, metabolism and toxicity [J].
Bodó, A ;
Bakos, E ;
Szeri, F ;
Váradi, A ;
Sarkadi, B .
TOXICOLOGY LETTERS, 2003, 140 :133-143
[5]   HG-829 Is a Potent Noncompetitive Inhibitor of the ATP-Binding Cassette Multidrug Resistance Transporter ABCB1 [J].
Caceres, Gisela ;
Robey, Robert W. ;
Sokol, Lubomir ;
McGraw, Kathy L. ;
Clark, Justine ;
Lawrence, Nicholas J. ;
Sebti, Said M. ;
Wiese, Michael ;
List, Alan F. .
CANCER RESEARCH, 2012, 72 (16) :4204-4213
[6]   Expression and functional activity of breast cancer resistance protein (BCRP, ABCG2) transporter in the human choriocarcinoma cell line bewo [J].
Ceckova, M ;
Libra, A ;
Pavek, P ;
Nachtigal, P ;
Brabec, M ;
Fuchs, R ;
Staud, F .
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2006, 33 (1-2) :58-65
[7]   QUANTITATIVE-ANALYSIS OF DOSE-EFFECT RELATIONSHIPS - THE COMBINED EFFECTS OF MULTIPLE-DRUGS OR ENZYME-INHIBITORS [J].
CHOU, TC ;
TALALAY, P .
ADVANCES IN ENZYME REGULATION, 1984, 22 :27-55
[8]   Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies [J].
Chou, Ting-Chao .
PHARMACOLOGICAL REVIEWS, 2006, 58 (03) :621-681
[9]   Species differences in drug transporters and implications for translating preclinical findings to humans [J].
Chu, Xiaoyan ;
Bleasby, Kelly ;
Evers, Raymond .
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2013, 9 (03) :237-252
[10]   The CDK inhibitors in cancer research and therapy [J].
Cicenas, Jonas ;
Valius, Mindaugas .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2011, 137 (10) :1409-1418